Advertisement

Prescribing and dispensing guidelines for medicinal drugs affecting driving performance

  • Johan J. de Gier
  • F. Javier Alvarez
  • Charles Mercier-Guyon
  • Alain G. Verstraete

Abstract

This chapter aims to provide practice-oriented information for prescribing physicians and dispensing pharmacists who want to provide their patients with adequate advice based on a clear understanding of the risks of accident involvement under different treatment conditions. Specific attention will be given to the application of a graded-level warning system based on categorization systems for psychotropic medicines that have been introduced,, and sometimes legally implemented, in several European countries. This warning system allows physicians and pharmacists to select the least impairing medicines within a therapeutic class. Advice for the patient based on three categories has been described in clear instructions, allowing the patient to make the right decision.

For the most frequently used drug classes (antihistamines, antidepressants, hypnotics and tranquillizers) information will be provided on drugs with little or no impairment within the respective classes, and risk factors (e.g. liver and./or renal dysfunction, drug-drug interactions) that might increase impairing effects. If drugs with little or no impairment can not be prescribed, specific patient information will focus on recognizing signs of impaired performance.

Keywords

Blood Alcohol Concentration Medicinal Drug Accident Involvement Operate Motor Vehicle 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Herings RMC (1994) Geneesmiddelen als determinant van ongevallen [Medicinal drugs as determinants of accidents]. Utrecht University, The Netherlands.Google Scholar
  2. 2.
    Hemmelgarn B, Suissa S, Huang A, Boivin J-F, Pinard G (1997) Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA 278: 27–31PubMedCrossRefGoogle Scholar
  3. 3.
    Neutel CI (1998) Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol Clin Exp 13: S115–123CrossRefGoogle Scholar
  4. 4.
    Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG and MacDonald TM (1998) Association of road-traffic accidents with benzodiazepine use. Lancet 352: 1331–1336PubMedCrossRefGoogle Scholar
  5. 5.
    Borkenstein RF, Crowther RF, Shumate RP, Ziel WB, Zylman R (1974) The role of the drinking driver in traffic accidents (the Grand Rapids Study). Blutalkohol 11: Supplement 1Google Scholar
  6. 6.
    Neutel CI (1995) Risk of traffic accident injury after a prescription for a benzodiazepine. Ann Epidemiol 5: 239–244PubMedCrossRefGoogle Scholar
  7. 7.
    Wolschrijn H, De Gier JJ, De Smet PAGM (1991) Drugs and driving: a new categorization system for drugs affecting psychomotor performance. Institute for drugs, safety and behaviour, University of Limburg, Maastricht, IVGV 91–24Google Scholar
  8. 8.
    De Gier JJ (1998) Drugs and driving research: application of results by drug regulatory authorities. Hum. Psychopharmacol. Clin. Exp 13: S133–S136CrossRefGoogle Scholar
  9. 9.
    Alvarez FJ, Del Río MC (2002) Medicinal drugs and driving: from research to clinical practice. Trends Pharmacol Sci 23: 441–445CrossRefGoogle Scholar
  10. 10.
    Grenez OE, Charlier CJ, Maes VA, Smet HC, Verstraete AG, Wennig RM, De Vrieze NE (1999) Influence des médicaments sur la conduite d’un véhicule. Etude de la litérature. Institute Belge pour la Sécurité Routiére (IBSR) and the Toxicological Society of Belgium and Luxembourg (BLT), BrusselsGoogle Scholar
  11. 11.
    Del Río MC, Alvarez JF, Gonzàlez-Luque JC (2002) Guía de prescripción farmacológica y seguridad vial [The Pharmaceutical Prescription Guidelines and Road Safety], 2nd Ed. Direccion General de Tràfico, MadrGoogle Scholar
  12. 12.
    Ministére de la Santé et des Solidarités, Arrêté du 18 juillet 2005 pris pour l’application de l’article R.5121-139 du code de la santé publique et relative à l’opposition d’un pictogramme sur le conditionnement extérieur de certain médicaments et produits. Journal Officiel de la République Française, 2 août 2005 (SAN/P0522726A).Google Scholar
  13. 13.
    Zorec Karlovšek M (2007) Medicinal Drugs and Traffic Safety. In: Zorec Karlovšek M (ed): Zdravila in prometna varnost Medical Faculty University of Ljubljana, Ljubljana, 41–59Google Scholar
  14. 14.
    Faber E, Brons M, Bruring DP, Hamelinck MAF, Jans PGW, Joppe GM, Van der Kwaakvan Hout HMA, Meijer-Toussaint CJM, Wolswinkel N (2008) LESA Geneesmiddelen en verkeersveiligheid [Medicinal drugs and traffic safety]. Huisarts Wet 51(6): S1–S4Google Scholar
  15. 15.
    Real Decreto 1345/2007, de 11 de octobre, por el que se regula el procedimiento de autorizacion, registro y condiciones de dispensacion de los medicamentos de uso humano fabricados industrialmente. BOE de 7 de Noviembre de 2007, pp: 45652–45698Google Scholar

Copyright information

© Birkhäuser Verlag/Switzerland 2009

Authors and Affiliations

  • Johan J. de Gier
    • 1
  • F. Javier Alvarez
    • 2
  • Charles Mercier-Guyon
    • 3
  • Alain G. Verstraete
    • 4
  1. 1.University of GroningenDepartment of Pharmacotherapy and Pharmaceutical CareGroningenThe Netherlands
  2. 2.Pharmacology and Therapeutics, Faculty of MedicineUniversity of ValladolidValladolidSpain
  3. 3.CERMT (Centre d’Études et de Recherches en Médecine du Traffic)AnnecyFrance
  4. 4.Department of Clinical Chemistry, Microbiology and ImmunologyGhent University, Belgium, Laboratory of Clinical Biology — Toxicology, Ghent University HospitalDe Pintelaan 185GhentBelgium

Personalised recommendations